Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 69   

Articles published

BMY 58.80 +0.19 (0.32%)
price chart
Bristol-Myers Squibb and AstraZeneca Expand Diabetes Alliance Through ...
PRINCETON, N.J., LONDON, & SAN DIEGO--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) announced today that Bristol-Myers Squibb will acquire Amylin for $31.00 per share in cash, ...
Bristol-Myers to buy Amylin for about $5.3 billion  Reuters
Bristol to Buy Amylin in $5.3 Billion Deal  Wall Street Journal
Related articles »  
BBDO, CDM Said to Win Big Bristol-Myers Squibb Brand
Omnicom agencies BBDO New York and The CDM Group have been given U.S. creative lead responsibilities for Bristol-Myers Squibb's Abilify antidepressant drug, sources said. The brand, which had been at Digitas Health, spent $133.7 million in U.S. ...
Bristol-Myers Squibb - Abilify
And finally... There is Bristol-Myers ($BMY) and its bad behavior. Its 2007 settlement covered a number of violations, such as gaming the system to jack up prices on Serzone.
Bristol-Myers Squibb and Pfizer Receive Complete Response Letter from U.S. ...
PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) announced that the U.S.
Pfizer, Bristol-Myers Squibb receive FDA CRL for ELIQUIS NDA
Related articles »  
Dying man fights to get experimental drug from Bristol-Myers Squibb
The company empathizes with patients who have limited treatment options, said spokeswoman Sonia Choi in a statement Sunday.
Related articles »  
Bristol-Myers Squibb and Emory University Announce Partnership to Advance ...
PRINCETON, N.J. & ATLANTA--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Emory University today announced the formation of a strategic partnership to conduct clinical trials involving Bristol-Myers Squibb's investigational ...
Related articles »  
Interim results from Bristol-Myers Squibb's BMS-936558 Phase 1 study on ...
Bristol-Myers Squibb Company (NYSE: BMY) today announced interim results from the expanded Phase 1 dose-ranging study 003 (n=296) of its investigational anti-PD-1 immunotherapy (BMS-936558), which showed clinical activity in patients with ...
Related articles »  
Bristol-Myers Immune Drug Puts Deadly Cancers on Hold in Study
The early success of an experimental drug from Bristol-Myers Squibb Co. that's designed to unleash the body's immune-system defenses against cancer sets the stage for an industry wide race to produce similar treatments.
Related articles »  
Otsuka, Bristol-Myers Squibb announce six-year data from SPRYCEL Phase 3 ...
Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Europe Ltd., today announced six-year follow-up results from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL´┐Ż (dasatinib) in Philadelphia ...
Related articles »  
Terminally ill patients should have access to last-chance therapies
His oncologist recommends that he be given the drug, BMS-936558, saying it may help. But Bristol-Myers Squibb has denied the request, saying it has a responsibility to protect patient safety in the research and development of its medicines.